Laboratory Medicine ›› 2026, Vol. 41 ›› Issue (10): 940-946.DOI: 10.3969/j.issn.1673-8640.2026.10.002
Previous Articles Next Articles
LIU Xiaoli1, LI Enling2, YU Chongzhao2, ZHENG Bing2(
)
Received:2025-06-19
Revised:2026-04-15
Online:2026-10-30
Published:2026-10-20
CLC Number:
LIU Xiaoli, LI Enling, YU Chongzhao, ZHENG Bing. Influence of different ANA statuses on the diagnosis of CTD in anti-SS-A/Ro60 antibody positivity[J]. Laboratory Medicine, 2026, 41(10): 940-946.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2026.10.002
| 组别 | 抗Ro52抗体 | 抗SS-B/La抗体 | 抗dsDNA抗体 | 抗nRNP抗体 | AnuA | 抗Rib-P抗体 | AHA |
|---|---|---|---|---|---|---|---|
| ANA-/Ro60+组 | 46(11.0) | 4(1.0) | 0(0.0) | 6(1.4) | 0(0.0) | 5(1.2) | 3(0.7) |
| ANA+/Ro60+组 | 8 110(73.7) | 2 350(21.4) | 2 174(19.7) | 1 941(17.6) | 1 414(12.8) | 998(9.1) | 801(7.3) |
| χ2值 | 777.1 | 102.7 | 102.2 | 74.97 | 61.44 | 31.26 | 26.57 |
| 校正P值 | <0.000 1 | <0.000 1 | <0.000 1 | <0.000 1 | <0.000 1 | <0.000 1 | <0.000 1 |
| 合计 | 8 156(71.4) | 2 354(20.6) | 2 174(19.0) | 1 947(17.0) | 1 414(12.4) | 1 003(8.8) | 804(7.0) |
| 组别 | AMA-M2 | 抗Sm抗体 | 抗CENP-B抗体 | 抗Jo-1抗体 | 抗Scl-70抗体 | 抗PM-Scl抗体 | 抗PCNA抗体 |
| ANA-/Ro60+组 | 13(3.1) | 0(0.0) | 1(0.2) | 6(1.4) | 1(0.2) | 2(0.5) | 1(0.2) |
| ANA+/Ro60+组 | 762(6.9) | 669(6.1) | 526(4.8) | 129(1.2) | 115(1.0) | 71(0.6) | 55(0.5) |
| χ2值 | 9.32 | 26.86 | 18.91 | 0.23 | 2.61 | 0.17 | 0.56 |
| 校正P值 | 0.032 | <0.000 1 | <0.000 1 | 1.000 0 | 1.000 0 | 1.000 0 | 1.000 0 |
| 合计 | 775(6.8) | 669(5.9) | 527(4.6) | 135(1.2) | 116(1.0) | 73(0.6) | 56(0.5) |
| 组别 | 抗Ro52抗体 | 抗SS-B/La抗体 | 抗dsDNA抗体 | 抗nRNP抗体 | AnuA | 抗Rib-P抗体 | AHA |
|---|---|---|---|---|---|---|---|
| ANA-/Ro60+组 | 46(11.0) | 4(1.0) | 0(0.0) | 6(1.4) | 0(0.0) | 5(1.2) | 3(0.7) |
| ANA+/Ro60+组 | 8 110(73.7) | 2 350(21.4) | 2 174(19.7) | 1 941(17.6) | 1 414(12.8) | 998(9.1) | 801(7.3) |
| χ2值 | 777.1 | 102.7 | 102.2 | 74.97 | 61.44 | 31.26 | 26.57 |
| 校正P值 | <0.000 1 | <0.000 1 | <0.000 1 | <0.000 1 | <0.000 1 | <0.000 1 | <0.000 1 |
| 合计 | 8 156(71.4) | 2 354(20.6) | 2 174(19.0) | 1 947(17.0) | 1 414(12.4) | 1 003(8.8) | 804(7.0) |
| 组别 | AMA-M2 | 抗Sm抗体 | 抗CENP-B抗体 | 抗Jo-1抗体 | 抗Scl-70抗体 | 抗PM-Scl抗体 | 抗PCNA抗体 |
| ANA-/Ro60+组 | 13(3.1) | 0(0.0) | 1(0.2) | 6(1.4) | 1(0.2) | 2(0.5) | 1(0.2) |
| ANA+/Ro60+组 | 762(6.9) | 669(6.1) | 526(4.8) | 129(1.2) | 115(1.0) | 71(0.6) | 55(0.5) |
| χ2值 | 9.32 | 26.86 | 18.91 | 0.23 | 2.61 | 0.17 | 0.56 |
| 校正P值 | 0.032 | <0.000 1 | <0.000 1 | 1.000 0 | 1.000 0 | 1.000 0 | 1.000 0 |
| 合计 | 775(6.8) | 669(5.9) | 527(4.6) | 135(1.2) | 116(1.0) | 73(0.6) | 56(0.5) |
| 组别 | 例数 | CTD | |||||||
|---|---|---|---|---|---|---|---|---|---|
| SLE | SS | UCTD | RA | ||||||
| 确诊/[例(%)] | OR值(95%CI) | 确诊/[例(%)] | OR值(95%CI) | 确诊/[例(%)] | OR值(95%CI) | 确诊/[例(%)] | OR值(95%CI) | ||
| ANA+/Ro60+组 | 11 005 | 3 094 (28.11) | 6.73(4.414~ 10.273) | 2 060 (18.72) | 3.79(2.503~ 5.739) | 1 107 (10.06) | 3.01(1.792~ 5.062) | 271 (2.46) | 1.30(0.638~ 2.638) |
| ANA-/Ro60+组 | 419 | 23 (5.49) | 0.15(0.097~ 0.227) | 24 (5.73) | 0.26(0.174~ 0.399) | 15 (3.58) | 0.33(0.198~ 0.558) | 8 (1.90) | 0.77(0.379~ 1.568) |
| χ2值 | 104.1 | 45.67 | 19.13 | 0.52 | |||||
| P值① | <0.000 1 | <0.000 1 | <0.000 1 | <0.000 1 | <0.000 1 | <0.000 1 | 1 | 0.473 | |
| 组别 | 罕见CTD② | ||||||||
| 多肌炎/皮肌炎 | SSc | 血管炎 | |||||||
| 确诊/[例(%)] | OR值(95%CI) | 确诊/[例(%)] | OR值(95%CI) | 确诊/[例(%)] | OR值(95%CI) | ||||
| ANA+/Ro60+组 | 48 (0.44) | 3.71(0.229~ 60.326) | 40 (3.60) | 3.10(0.190~ 50.480) | 20 (0.18) | 1.57(0.095~ 25.930) | |||
| ANA-/Ro60+组 | 0 (0.00) | 0.27(0.017~ 4.374) | 0 (0.00) | 0.32(0.020~ 5.257) | 0 (0.00) | 0.64(0.039~ 10.578) | |||
| χ2值 | 1.84 | 1.52 | 0.76 | ||||||
| P值① | 0.170 0 | 0.356 0 | 0.210 0 | 0.427 0 | 0.380 0 | 0.754 0 | |||
| 组别 | 其他疾病 | ||||||||
| 其他AID③ | 非AID | ||||||||
| RSA | CKD | 肠炎 | |||||||
| 确诊/[例(%)] | OR值(95%CI) | 确诊/[例(%)] | OR值(95%CI) | 确诊/[例(%)] | OR值(95%CI) | 确诊/[例(%)] | OR值(95%CI) | ||
| ANA+/Ro60+组 | 148 (1.34) | 0.46(0.255~ 0.840) | 227 (2.06) | 0.22(0.151~ 0.312) | 78 (0.70) | 0.33(0.162~ 0.653) | 22 (0.20) | 0.21(0.071~ 0.606) | |
| ANA-/Ro60+组 | 11 (2.86) | 2.16(1.191~ 3.927) | 37 (8.80) | 4.60(3.202~ 6.606) | 9 (2.15) | 3.08(1.532~ 6.174) | 4 (0.95) | 4.81(1.651~ 14.026) | |
| χ2值 | 6.745 | 81.89 | 11.06 | 10.13 | |||||
| P值① | 0.028 | 0.010 0 | <0.000 1 | <0.000 1 | 0.000 9 | 0.002 0 | 0.001 5 | 0.004 0 | |
| 组别 | 例数 | CTD | |||||||
|---|---|---|---|---|---|---|---|---|---|
| SLE | SS | UCTD | RA | ||||||
| 确诊/[例(%)] | OR值(95%CI) | 确诊/[例(%)] | OR值(95%CI) | 确诊/[例(%)] | OR值(95%CI) | 确诊/[例(%)] | OR值(95%CI) | ||
| ANA+/Ro60+组 | 11 005 | 3 094 (28.11) | 6.73(4.414~ 10.273) | 2 060 (18.72) | 3.79(2.503~ 5.739) | 1 107 (10.06) | 3.01(1.792~ 5.062) | 271 (2.46) | 1.30(0.638~ 2.638) |
| ANA-/Ro60+组 | 419 | 23 (5.49) | 0.15(0.097~ 0.227) | 24 (5.73) | 0.26(0.174~ 0.399) | 15 (3.58) | 0.33(0.198~ 0.558) | 8 (1.90) | 0.77(0.379~ 1.568) |
| χ2值 | 104.1 | 45.67 | 19.13 | 0.52 | |||||
| P值① | <0.000 1 | <0.000 1 | <0.000 1 | <0.000 1 | <0.000 1 | <0.000 1 | 1 | 0.473 | |
| 组别 | 罕见CTD② | ||||||||
| 多肌炎/皮肌炎 | SSc | 血管炎 | |||||||
| 确诊/[例(%)] | OR值(95%CI) | 确诊/[例(%)] | OR值(95%CI) | 确诊/[例(%)] | OR值(95%CI) | ||||
| ANA+/Ro60+组 | 48 (0.44) | 3.71(0.229~ 60.326) | 40 (3.60) | 3.10(0.190~ 50.480) | 20 (0.18) | 1.57(0.095~ 25.930) | |||
| ANA-/Ro60+组 | 0 (0.00) | 0.27(0.017~ 4.374) | 0 (0.00) | 0.32(0.020~ 5.257) | 0 (0.00) | 0.64(0.039~ 10.578) | |||
| χ2值 | 1.84 | 1.52 | 0.76 | ||||||
| P值① | 0.170 0 | 0.356 0 | 0.210 0 | 0.427 0 | 0.380 0 | 0.754 0 | |||
| 组别 | 其他疾病 | ||||||||
| 其他AID③ | 非AID | ||||||||
| RSA | CKD | 肠炎 | |||||||
| 确诊/[例(%)] | OR值(95%CI) | 确诊/[例(%)] | OR值(95%CI) | 确诊/[例(%)] | OR值(95%CI) | 确诊/[例(%)] | OR值(95%CI) | ||
| ANA+/Ro60+组 | 148 (1.34) | 0.46(0.255~ 0.840) | 227 (2.06) | 0.22(0.151~ 0.312) | 78 (0.70) | 0.33(0.162~ 0.653) | 22 (0.20) | 0.21(0.071~ 0.606) | |
| ANA-/Ro60+组 | 11 (2.86) | 2.16(1.191~ 3.927) | 37 (8.80) | 4.60(3.202~ 6.606) | 9 (2.15) | 3.08(1.532~ 6.174) | 4 (0.95) | 4.81(1.651~ 14.026) | |
| χ2值 | 6.745 | 81.89 | 11.06 | 10.13 | |||||
| P值① | 0.028 | 0.010 0 | <0.000 1 | <0.000 1 | 0.000 9 | 0.002 0 | 0.001 5 | 0.004 0 | |
| [1] |
Bonroy C, Vercammen M, Fierz W, et al. Detection of antinuclear antibodies:recommendations from EFLM,EASI and ICAP[J]. Clin Chem Lab Med, 2023, 61(7):1167-1198.
DOI URL |
| [2] | 中国中西医结合学会检验医学专业委员会, 上海市医学会检验医学专科分会, 李敏, 等. 间接免疫荧光法用于抗核抗体实验室检测的中国专家共识(2023年)[J]. 中华检验医学杂志, 2023, 46(11):1149-1163. |
| [3] |
Damoiseaux J, Andrade L E C, Carballo O G, et al. Clinical relevance of HEp-2 indirect immunofluorescent patterns:the International Consensus on ANA patterns(ICAP) perspective[J]. Ann Rheum Dis, 2019, 78(7):879-889.
DOI PMID |
| [4] |
Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus[J]. Ann Rheum Dis, 2019, 78(9):1151-1159.
DOI PMID |
| [5] | 中华医学会风湿病学分会, 国家皮肤与免疫疾病临床医学研究中心, 中国系统性红斑狼疮研究协作组. 2020中国系统性红斑狼疮诊疗指南[J]. 中华内科杂志, 2020, 59(3):172-185. |
| [6] |
Anis S, Fatima A, Abdul Jabbar S, et al. ANA-specific antibodies,ANA patterns,anti-ds-DNA results,and clinical diagnosis:a laboratory and clinical audit[J]. Immunol Res, 2023, 71(2):267-275.
DOI |
| [7] |
Zhao L, Wang W, Wu L, et al. Combination of anti-SSA/Ro60 and anti-dsDNA serotype is predictive of belimumab renal response in patients with lupus nephritis[J]. Lupus Sci Med, 2024, 11(1):e001156.
DOI URL |
| [8] |
Shiboski C H, Shiboski S C, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome:a consensus and data-driven methodology involving three international patient cohorts[J]. Arthritis Rheumatol, 2017, 69(1):35-45.
DOI URL |
| [9] |
Andrade L E C, Klotz W, Herold M, et al. Reflecting on a decade of the international consensus on ANA patterns(ICAP):accomplishments and challenges from the perspective of the 7th ICAP workshop[J]. Autoimmun Rev, 2024, 23(9):103608.
DOI URL |
| [10] |
Rodríguez-orozco A R, Béjar-lozano C, Cortés-rojo C. Antibodies to extractable nuclear antigens are detectable in a considerable number of sera that test negative for antinuclear antibodies[J]. Arch Pathol Lab Med, 2022, 146(2):143-144.
DOI PMID |
| [11] |
Mierau R. Antinuclear antibodies without connective tissue disease:antibodies against LEDGF/DSF70[J]. Z Rheumatol, 2016, 75(4):372-380.
DOI PMID |
| [12] | Wongjarit K, Thammacharoenrach N, Dityen K, et al. Determination of specific autoantibodies in patients with systemic lupus erythematosus by line immunoassay,ELISA and CLIF assay[J]. Asian Pac J Allergy Immunol, 2023, 41(1):73-79. |
| [13] |
Singh A, Sahu S, Jadhav N R, et al. Hep-2000 indirect immunofluorescence assay-an emerging screening tool for detection of antinuclear autoantibodies in various connective tissue disorders[J]. Indian J Pathol Microbiol, 2024, 67(4):841-845.
DOI URL |
| [14] |
Denvir B, Carlucci P M, Corbitt K, et al. Prevalence of concomitant rheumatologic diseases and autoantibody specificities among racial and ethnic groups in SLE patients[J]. Front Epidemiol, 2024, 4:1334859.
DOI URL |
| [15] |
Lou H, Ling G S, Cao X. Autoantibodies in systemic lupus erythematosus:from immunopathology to therapeutic target[J]. J Autoimmun, 2022, 132:102861.
DOI URL |
| [16] | Zandman-goddard G, Gilburd B, Shovman O, et al. The homogeneous multiplexed system-a new method for autoantibody profile in systemic lupus erythematosus[J]. Clin Dev Immunol, 2005, 12(2):107-111. |
| [17] |
Mavragani C P, Moutsopoulos H M. Sjögren's syndrome:old and new therapeutic targets[J]. J Autoimmun, 2020, 110:102364.
DOI URL |
| [18] | 胡朝军, 李俊, 张道强, 等. 间接免疫荧光法筛查抗核抗体与特异性抗体检测的相互关系[J]. 中华临床免疫和变态反应杂志, 2011, 5(3):179-185. |
| [19] | 陈振兴, 甄广怀, 李新亮, 等. 多种自身抗体联合检测方法在自身免疫性疾病诊断中的临床意义[J]. 罕少疾病杂志, 2022, 29(4):108-109. |
| [20] |
Yamazoe M, Ting K K Y, Lee I H, et al. B cells promote atrial fibrillation via autoantibodies[J]. Nat Cardiovasc Res, 2025, 4(10):1381-1396.
DOI |
| [1] | WANG Junfen, YU Qi, LOU Jiatao, FAN Qiuling, ZHANG Rulin, ZHANG Rong, SUN Yi. Comparison of 4 anti-phospholipase A2 receptor antibody determination methods in the diagnosis of primary membranous nephropathy [J]. Laboratory Medicine, 2026, 41(9): 879-883. |
| [2] | GAO Limei, GAO Xiupan, ZENG Junxiang, YU Youyou, PAN Xiujun. Determination results of serum ANA and relation with disease in 7 803 children [J]. Laboratory Medicine, 2024, 39(6): 517-523. |
| [3] | HU Chuanxi, LIU Lingyan, LI Man. Clinical roles of indirect immunofluorescence assay,line immunoassay,chemiluminescent assay for determining antinuclear antibodies singly and in combination [J]. Laboratory Medicine, 2024, 39(11): 1072-1077. |
| [4] | DUAN Lili, JIANG Chang, ZHOU Dongmei. Role of PLR in ankylosing spondylitis patients with positive antinuclear antibody [J]. Laboratory Medicine, 2023, 38(7): 669-674. |
| [5] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
| [6] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
| [7] | ZHANG Cheng, YANG Ying, WU Shanshan, LÜ Dan, ZHANG Tingting. Role of multiplexed bead-based immunoassay in the determination of AAV [J]. Laboratory Medicine, 2019, 34(7): 633-636. |
| [8] | WANG Juan, SHEN Qingying, WANG Kaiwen, ZHAO Jiangfeng. Role of anti-chromatin antibody determined by automatic multiplex bead immunoassay in the diagnosis of connective tissue diseases [J]. Laboratory Medicine, 2019, 34(11): 1021-1025. |
| [9] | XU Ping, YING Chunmei, FANG Yun. Role of antinuclear antibody determination in the diagnosis of infertility [J]. Laboratory Medicine, 2018, 33(12): 1116-1119. |
| [10] | ZHAN Wenli, LI Lixin, HUANG Zhuochun, HU Jing, WU Yongkang. Consistency of 2 systems for the determination of antinuclear antibody profile [J]. Laboratory Medicine, 2016, 31(11): 969-973. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||